Document is current
Any future updates will be listed below
-
Authors
Dreyer, Timothy J. https://orcid.org/0000-0001-7460-7292
Keen, Jacob A. C.
Wells, Leah M.
Hopkinson, Mark
Orriss, Isabel R. https://orcid.org/0000-0002-7847-050X
Holdsworth, Gill https://orcid.org/0000-0002-9979-8694
Pitsillides, Andrew A. https://orcid.org/0000-0002-3861-998X
Roberts, Scott J.
-
Funding
Funding for this research was provided by:
UCB Pharma, 216 Bath Road, Slough, United Kingdom, SL1 3WE. Grant recipient is Scott Roberts.
- License Information
-
More Information
Article History
Received: 31 May 2024
Revised: 22 January 2025
Accepted: 30 January 2025
First Online: 7 April 2025
Competing interests
: GH is employed by and holds stock in UCB Pharma. SJR is a previous employee of UCB Pharma and is in receipt of research funding from UCB Pharma to investigate sclerostin biology in the context of Sclerosteosis. TJD is a sclerosteosis patient and fundraises for patient activities. JACK, LMW, MH, IO and AAP have no conflicts of interest that could be perceived as prejudicing the impartiality of this paper.
